Novavax - 27 Year Stock Price History | NVAX

Historical daily share price chart and data for Novavax since 1995 adjusted for splits. The latest closing stock price for Novavax as of August 10, 2022 is 41.36.
  • The all-time high Novavax stock closing price was 319.93 on February 08, 2021.
  • The Novavax 52-week high stock price is 277.80, which is 571.7% above the current share price.
  • The Novavax 52-week low stock price is 34.88, which is 15.7% below the current share price.
  • The average Novavax stock price for the last 52 weeks is 117.77.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novavax Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 68.2905 142.9000 142.9000 36.2800 41.3600 -71.09%
2021 193.6511 112.9800 319.9300 112.9800 143.0700 28.30%
2020 69.3011 4.4900 178.5100 3.9300 111.5100 2701.76%
2019 12.1012 39.4000 46.8000 3.6900 3.9800 -89.18%
2018 35.1765 26.0000 49.6000 23.4000 36.8000 48.39%
2017 23.4596 25.4000 32.6000 14.6800 24.8000 -1.59%
2016 95.1524 157.6000 166.8000 23.6000 25.2000 -84.98%
2015 179.2758 115.2000 282.8000 114.8000 167.8000 41.48%
2014 98.5063 104.2000 133.0000 73.8000 118.6000 15.82%
2013 52.5332 39.4000 103.2000 35.0000 102.4000 170.90%
2012 33.0187 27.6000 47.8000 23.2000 37.8000 50.00%
2011 39.4103 51.4000 59.2000 23.6000 25.2000 -48.15%
2010 47.0562 56.2000 60.4000 40.2000 48.6000 -8.65%
2009 56.0539 40.4000 133.0000 11.2000 53.2000 40.74%
2008 51.5972 65.2000 70.6000 27.6000 37.8000 -43.24%
2007 67.2954 77.4000 90.0000 51.8000 66.6000 -18.78%
2006 93.8374 77.6000 166.2000 56.8000 82.0000 6.49%
2005 42.3058 64.8000 110.6000 14.8000 77.0000 18.10%
2004 92.4413 120.2000 138.4000 58.6000 65.2000 -45.67%
2003 102.6408 56.0000 164.4200 52.7800 120.0000 130.77%
2002 120.5912 272.4000 272.4000 37.2000 52.0000 -81.56%
2001 213.7363 168.2000 300.6000 138.8000 282.0000 65.88%
2000 152.4373 115.0000 231.2000 95.0000 170.0000 51.25%
1999 77.3056 40.0000 118.8000 38.8000 112.4000 189.69%
1998 66.5198 101.2000 116.2000 27.6000 38.8000 -61.20%
1997 87.7589 67.6000 115.0000 60.0000 100.0000 45.35%
1996 98.8654 80.0000 162.4000 60.0000 68.8000 -8.27%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.147B $1.146B
Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.?Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.?Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.?ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00